Vasomotor symptoms during menopause: a practical guide on current treatments and future perspectives
SJ Khan, E Kapoor, SS Faubion… - International Journal of …, 2023 - Taylor & Francis
Vasomotor symptoms affect as many as 80% of midlife women, but only about one in four
women receive treatment due to many factors. Menopausal hormone therapy remains the …
women receive treatment due to many factors. Menopausal hormone therapy remains the …
Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society
This care pathway from the European Menopause and Andropause Society (EMAS)
provides an updated pathway for monitoring and guidance of women at midlife, focusing on …
provides an updated pathway for monitoring and guidance of women at midlife, focusing on …
Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial
H Depypere, D Timmerman, G Donders… - The Journal of …, 2019 - academic.oup.com
Context The thermoregulatory center in the hypothalamus is stimulated by neurokinin 3
receptor (NK3R) activation and inhibited by estrogen-negative feedback. This balance is …
receptor (NK3R) activation and inhibited by estrogen-negative feedback. This balance is …
[HTML][HTML] A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms …
GL Fraser, S Lederman, A Waldbaum, R Kroll… - Menopause, 2020 - journals.lww.com
Objective: Menopausal vasomotor symptoms (VMS) may result from altered
thermoregulatory control in brain regions innervated by neurokinin 3 receptor-expressing …
thermoregulatory control in brain regions innervated by neurokinin 3 receptor-expressing …
[HTML][HTML] Efficacy and safety of elinzanetant, a selective neurokinin-1, 3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)
JA Simon, RA Anderson, E Ballantyne, J Bolognese… - Menopause, 2023 - journals.lww.com
Objective Neurokinin (NK)-3 and NK-1 receptors have been implicated in the etiology of
vasomotor symptoms (VMS) and sleep disturbances associated with menopause. This …
vasomotor symptoms (VMS) and sleep disturbances associated with menopause. This …
Hormone therapy in menopause
J Paciuc - Hormonal Pathology of the Uterus, 2020 - Springer
As longevity expands, women are spending a third of their existence in menopause and
beyond. The vast majority suffer from symptoms that negatively impact their quality of life …
beyond. The vast majority suffer from symptoms that negatively impact their quality of life …
Kisspeptin/Neurokinin B/Dynorphin (KNDy) cells as integrators of diverse internal and external cues: evidence from viral-based monosynaptic tract-tracing in mice
Neurons in the hypothalamic arcuate nucleus (ARC) that co-express kisspeptin, neurokinin
B and dynorphin (KNDy cells) are essential for mammalian reproduction as key regulators of …
B and dynorphin (KNDy cells) are essential for mammalian reproduction as key regulators of …
Neurokinin 3 receptor antagonists compared with serotonin norepinephrine reuptake inhibitors for non-hormonal treatment of menopausal hot flushes: a systematic …
SJ Menown, JA Tello - Advances in therapy, 2021 - Springer
Abstract Introduction Hot flushes/flashes (HFs) or other vasomotor symptoms affect between
45 and 97% of women during menopause. Hormone replacement therapy (HRT) is effective …
45 and 97% of women during menopause. Hormone replacement therapy (HRT) is effective …
[HTML][HTML] Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy
Background: Over 75% of menopausal women experience vasomotor symptoms (VMS),
such as night sweats and hot flashes. Despite the prevalence of these symptoms, there is …
such as night sweats and hot flashes. Despite the prevalence of these symptoms, there is …